PUBLIC COMPANY
save$STOKStoke Therapeutics, Inc.
$STOK26.41-0.83%Bedford, MA, USupdated 12h ago
community read0 votes
pipeline
1
marketed
0
phase 3
1
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 3
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (1)
Active trials
- phase3A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
- phase2An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome
- phase2An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome
🐶 Hiring Signal
Where Stoke Therapeutics, Inc. is staffing up — a leading indicator of pipeline and commercial priorities.
therapeutic areaCNS / Neuroscience 1Ophthalmology 1
News
- Vir says hepatitis D drug combination succeeds in first pivotal studyVir Biotechnology’s chronic hepatitis D treatment has succeeded in the first of three late-stage studies, stoking competition with Gilead and Mirum Pharmaceuticals. Vir said Sunday afternoon that 4…endpoints · 9d ago
Data sources
last refreshed 42m ago
Found something off?
comments(0)
5-min edit window · permanent after that